CPG2 Hormonal Replacement in Hypopituitarism: An Endocrine Society Clinical Practice Guideline

Program: Clinical Practice Guidelines
Clinical Session
Saturday, April 2, 2016: 8:30 AM-9:30 AM
Hall B2 (BCEC)
Steven G Waguespack, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
Maria Fleseriu, MD, FACE, Northwest Pituitary Center, Oregon Health & Science University, Portland, OR
Task Force Participants:
Ibrahim A Hashim, PhD, University of Texas Southwestern Medical Center, Dallas, TX , Niki Karavitaki, MsC, PhD, FRCP, Institute of Metabolism and Systems Research, University of Birmingham and Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom of Great Britain and Northern Ireland , Shlomo Melmed, MB, ChB, Cedars-Sinai Medical Center, Los Angeles, CA , Roberto Salvatori, MD, Johns Hopkins University, Baltimore, MD To Be Determined

MF: Principal Investigator, Ipsen, Principal Investigator, Novartis Pharmaceuticals, Principal Investigator, Pfizer Global R&D, Principal Investigator, Chiasma, Principal Investigator, Cortendo, Ad Hoc Consultant, Chiasma, Ad Hoc Consultant, Cortendo, Ad Hoc Consultant, Novartis Pharmaceuticals, Ad Hoc Consultant, Pfizer Global R&D. NK: Speaker, Novartis Pharmaceuticals, Speaker, Pfizer, Inc.. RS: Advisory Group Member, Novartis Pharmaceuticals, Advisory Group Member, Novo Nordisk. Nothing to Disclose: SGW, IAH, SM Disclosure Not Provided: SGW, MHS


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire